{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:43:15Z","timestamp":1786120995419,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Acute myeloid leukemia (AML) is predominantly a disease of older patients with a poor long-term survival. Approval of the combination of venetoclax (VEN) with azacitidine (AZA) or decitabine (DAC) in the European Union in 2021 for the treatment of patients with newly diagnosed AML who are ineligible for induction chemotherapy has become the treatment backbone for older, medically non-fit AML patients. Based on in vitro priming of AML cells to all-\n                      <jats:italic>trans<\/jats:italic>\n                      retinoic acid (ATRA) by DAC, we had previously conducted a randomized phase II trial (DECIDER, AMLSG 14\u2009\u2212\u200909) in 200 elderly, non-fit AML patients on the effect of ATRA as add-on to DAC. Median overall survival (OS) was 8.2 months with ATRA versus 5.1 months without ATRA (hazard ratio, 0.65; 95% CI, 0.48 to 0.89;\n                      <jats:italic>P<\/jats:italic>\n                      = 0.006). Notably, ATRA did not add toxicity, the combination was active also in patients with adverse genetics, and prolonged time to treatment resistance. Investigating a triple combination of DAC, VEN and ATRA was a logical next step. This randomized double-blind phase III trial compares the efficacy of ATRA versus placebo as add-on to the backbone treatment (DAC and VEN) with respect to OS, objective best response, quality of life and safety. The accompanying translational research will contribute to identify molecular markers for drug efficacy and better tailoring epigenetic therapy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>DECIDER-2 (AMLSG 32\u2009\u2212\u200921) is a prospective, randomized, double-blind, placebo-controlled, parallel group, multicenter trial. The primary study objective is to compare the efficacy of ATRA versus placebo as add-on to the backbone treatment (DAC and VEN) in terms of OS. The target population is adult AML patients unfit for standard induction chemotherapy. Patients are randomized (1:1) to receive backbone treatment in combination with either ATRA or placebo. Four interim safety analyses were planned with the involvement of the Data Monitoring Committee.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>This trial investigates whether the in vitro cooperativity of DAC, VEN, and ATRA prolongs OS in unfit AML patients compared to placebo, offering a novel, low-toxicity triplet combination with a promising risk-benefit ratio.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>EU CT number: 2020-005495-36\/2023-507461-26-00 (registered 18.11.2020); German clinical trials registry number: DRKS00023646 (registered 23.08.2022).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16617-8","type":"journal-article","created":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T01:13:44Z","timestamp":1785892424000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy"],"prefix":"10.1186","volume":"26","author":[{"given":"Olga","family":"Grishina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Schmoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Sellner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Hackanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iordanis","family":"Deligiannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felicitas","family":"Thol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Crysandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Junghanss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Runde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul La","family":"Ros\u00e9e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lino Lars","family":"Teichmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifa Kathrin","family":"Al-Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Sauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Germing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Griesinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Lukic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Krauter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Snjezana","family":"Janjetovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Koch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Staib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julian","family":"Topaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maike","family":"de Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris Maria","family":"Kraemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz","family":"Oelschl\u00e4ger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Schnetzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Schmah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swen","family":"Wessendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Khandanpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"K\u00fcndgen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Schwalenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Heuser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hartmut","family":"D\u00f6hner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"16617_CR1","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1056\/NEJMra1406184","volume":"373","author":"H D\u00f6hner","year":"2015","unstructured":"D\u00f6hner H, Weisdorf DJ, Bloomfield CD. Acute Myeloid Leukemia. N Engl J Med United States. 2015;373:1136\u201352. https:\/\/doi.org\/10.1056\/NEJMra1406184.","journal-title":"N Engl J Med United States"},{"key":"16617_CR2","doi-asserted-by":"publisher","first-page":"208","DOI":"10.3324\/haematol.2012.067892","volume":"98","author":"B Deschler","year":"2013","unstructured":"Deschler B, Ihorst G, Platzbecker U, Germing U, M\u00e4rz E, de Figuerido M, et al. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome. Haematologica. 2013;98:208\u201316. https:\/\/doi.org\/10.3324\/haematol.2012.067892.","journal-title":"Haematologica"},{"key":"16617_CR3","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1200\/JCO.2011.38.9429","volume":"30","author":"HM Kantarjian","year":"2012","unstructured":"Kantarjian HM, Thomas XG, Dmoszynska A, Wierzbowska A, Mazur G, Mayer J, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol. 2012;30:2670\u20137. https:\/\/doi.org\/10.1200\/JCO.2011.38.9429.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"16617_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A, Wierzbowska A, Selleslag D, Jang JH, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >\u200930% blasts. Blood. 2015;126:291. https:\/\/doi.org\/10.1182\/blood-2015-01-621664.","journal-title":"Blood"},{"key":"16617_CR5","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1056\/NEJMoa2012971","volume":"383","author":"CD DiNardo","year":"2020","unstructured":"DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, Wei AH, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383:617\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2012971.","journal-title":"N Engl J Med"},{"key":"16617_CR6","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1200\/JCO.19.01053","volume":"38","author":"M L\u00fcbbert","year":"2020","unstructured":"L\u00fcbbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, et al. Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 \u00d7 2, Phase II Trial. J Clin Oncol Wolters Kluwer. 2020;38:257\u201370. https:\/\/doi.org\/10.1200\/JCO.19.01053.","journal-title":"J Clin Oncol Wolters Kluwer"},{"key":"16617_CR7","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1182\/blood.2024024944","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, Pratz KW, DiNardo CD, Wei AH, Jonas BA, Pullarkat VA, et al. Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine. Blood United States. 2024;144:2211\u201322. https:\/\/doi.org\/10.1182\/blood.2024024944.","journal-title":"Blood United States"},{"key":"16617_CR8","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41409-021-01476-7","volume":"57","author":"DA Pollyea","year":"2022","unstructured":"Pollyea DA, Winters A, McMahon C, Schwartz M, Jordan CT, Rabinovitch R, et al. Venetoclax and azacitidine followed by allogeneic transplant results in excellent outcomes and may improve outcomes versus maintenance therapy among newly diagnosed AML patients older than 60. Bone Marrow Transpl Engl. 2022;57:160\u20136. https:\/\/doi.org\/10.1038\/s41409-021-01476-7.","journal-title":"Bone Marrow Transpl Engl"},{"key":"16617_CR9","doi-asserted-by":"publisher","first-page":"e830","DOI":"10.1016\/S2352-3026(24)00241-2","volume":"11","author":"D Russo","year":"2024","unstructured":"Russo D, Polverelli N, Bernardi S, Santarone S, Farina M, Borlenghi E, et al. Venetoclax plus decitabine as a bridge to allogeneic haematopoietic stem-cell transplantation in older patients with acute myeloid leukaemia (VEN-DEC GITMO): final report of a multicentre, single-arm, phase 2 trial. Lancet Haematol Engl. 2024;11:e830\u20138. https:\/\/doi.org\/10.1016\/S2352-3026(24)00241-2.","journal-title":"Lancet Haematol Engl"},{"key":"16617_CR10","doi-asserted-by":"publisher","first-page":"e879","DOI":"10.1016\/S2352-3026(23)00273-9","volume":"10","author":"M L\u00fcbbert","year":"2023","unstructured":"L\u00fcbbert M, Wijermans PW, Kicinski M, Chantepie S, Van der Velden WJFM, Noppeney R, et al. 10-day decitabine versus 3\u2008+\u20087 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. Lancet Haematol Engl. 2023;10:e879\u201389. https:\/\/doi.org\/10.1016\/S2352-3026(23)00273-9.","journal-title":"Lancet Haematol Engl"},{"key":"16617_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1182\/blood.2023023625","volume":"144","author":"F Efficace","year":"2024","unstructured":"Efficace F, Kicinski M, Coens C, Suciu S, van der Velden WJFM, Noppeney R, et al. Decitabine in older patients with AML: quality of life results of the EORTC-GIMEMA-GMDS-SG randomized phase 3 trial. Blood United States. 2024;144:541\u201351. https:\/\/doi.org\/10.1182\/blood.2023023625.","journal-title":"Blood United States"},{"key":"16617_CR12","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood.2024027217","volume":"145","author":"J Lu","year":"2025","unstructured":"Lu J, Xue S-L, Wang Y, He X-F, Hu X-H, Miao M, et al. Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML. Blood United States. 2025;145:2645\u201355. https:\/\/doi.org\/10.1182\/blood.2024027217.","journal-title":"Blood United States"},{"key":"16617_CR13","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1200\/JCO.23.01911","volume":"42","author":"NJ Short","year":"2024","unstructured":"Short NJ, Daver N, Dinardo CD, Kadia T, Nasr LF, Macaron W, et al. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol Off J Am Soc Clin Oncol United States. 2024;42:1499\u2013508. https:\/\/doi.org\/10.1200\/JCO.23.01911.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol United States"},{"key":"16617_CR14","doi-asserted-by":"publisher","first-page":"2692","DOI":"10.1200\/JCO-25-00640","volume":"43","author":"CD DiNardo","year":"2025","unstructured":"DiNardo CD, Marvin-Peek J, Loghavi S, Takahashi K, Issa GC, Jen W-Y, et al. Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML. J Clin Oncol Off J Am Soc Clin Oncol United States. 2025;43:2692\u20139. https:\/\/doi.org\/10.1200\/JCO-25-00640.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol United States"},{"key":"16617_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41408-025-01346-1","volume":"15","author":"N Gangat","year":"2025","unstructured":"Gangat N, DiNardo CD. Newly diagnosed acute myeloid leukemia in unfit patients: 2026 treatment algorithms. Blood Cancer J United States. 2025;15:139. https:\/\/doi.org\/10.1038\/s41408-025-01346-1.","journal-title":"Blood Cancer J United States"},{"key":"16617_CR16","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1182\/blood.2020010100","volume":"137","author":"M-C Geoffroy","year":"2021","unstructured":"Geoffroy M-C, Esnault C, de Th\u00e9 H. Retinoids in hematology: a timely revival? Blood United States. 2021;137:2429\u201337. https:\/\/doi.org\/10.1182\/blood.2020010100.","journal-title":"Blood United States"},{"key":"16617_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41408-022-00715-4","volume":"12","author":"R Meier","year":"2022","unstructured":"Meier R, Greve G, Zimmer D, Bresser H, Berberich B, Langova R, et al. The antileukemic activity of decitabine upon PML\/RARA-negative AML blasts is supported by all-trans retinoic acid: in vitro and in vivo evidence for cooperation. Blood Cancer J United States. 2022;12:122. https:\/\/doi.org\/10.1038\/s41408-022-00715-4.","journal-title":"Blood Cancer J United States"},{"key":"16617_CR18","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1038\/s41416-022-02074-0","volume":"128","author":"L Wang","year":"2023","unstructured":"Wang L, Zhang Q, Ye L, Ye X, Yang W, Zhang H, et al. All-trans retinoic acid enhances the cytotoxic effect of decitabine on myelodysplastic syndromes and acute myeloid leukaemia by activating the RAR\u03b1-Nrf2 complex. Br J Cancer Engl. 2023;128:691\u2013701. https:\/\/doi.org\/10.1038\/s41416-022-02074-0.","journal-title":"Br J Cancer Engl"},{"key":"16617_CR19","unstructured":"El Khawanky N, Nedelko T, Mandracci G, Barth Y, Rosenbaum M, Wei\u00df C et al. Intrinsic RNA receptor signaling in AML modulates 5\u2019-azacitidine efficacy and can be re-sensitizided during acquired resistance by all-trans retinoic acid. EHA. 2025. Cited 2025 May 14. https:\/\/library.ehaweb.org\/eha\/2025\/eha2025-congress\/4159209. Accessed 14 May 2025."},{"key":"16617_CR20","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1111\/ejh.14304","volume":"114","author":"H Bresser","year":"2025","unstructured":"Bresser H, Schmoor C, Grishina O, Pfeifer D, Thomas J, Rehman U-U, et al. Impact of TP53 Mutation Status in Elderly AML Patients When Adding All-Trans Retinoic Acid or Valproic Acid to Decitabine. Eur J Haematol Engl. 2025;114:231\u20137. https:\/\/doi.org\/10.1111\/ejh.14304.","journal-title":"Eur J Haematol Engl"},{"key":"16617_CR21","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2025.288526","author":"X Zhou","year":"2025","unstructured":"Zhou X, Lin Y, Gao Y, Ge Z, Huang L, Zhang J, et al. Decitabine plus all-trans retinoic acid versus decitabine monotherapy for myelodysplastic syndromes with excess blasts: a multicenter, randomized controlled trial. Haematol [Internet]. 2025. https:\/\/doi.org\/10.3324\/haematol.2025.288526. [cited 2025 Dec 1].","journal-title":"Haematol [Internet]"},{"key":"16617_CR22","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","volume":"129","author":"H D\u00f6hner","year":"2017","unstructured":"D\u00f6hner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, B\u00fcchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424. https:\/\/doi.org\/10.1182\/blood-2016-08-733196.","journal-title":"Blood"},{"key":"16617_CR23","volume-title":"EORTC QLQ-C30 scoring manual","author":"PM Fayers","year":"2001","unstructured":"Fayers PM, Aaronson NK, Bjordal K, Gr\u00f8nvold M, Curran D, Bottomley A. EORTC QLQ-C30 scoring manual. Brussels: European Organisation for Research and Treatment of Cancer; 2001."},{"key":"16617_CR24","unstructured":"Scoring of the FACIT measures. Scoring of the FACIT measures. https:\/\/www.facit.org\/scoring."},{"key":"16617_CR25","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1002\/cyto.b.22144","volume":"104","author":"JM Tettero","year":"2023","unstructured":"Tettero JM, Dakappagari N, Heidinga ME, Oussoren-Brockhoff Y, Hanekamp D, Pahuja A, et al. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry. Cytometry B Clin Cytom United States. 2023;104:426\u201339. https:\/\/doi.org\/10.1002\/cyto.b.22144.","journal-title":"Cytometry B Clin Cytom United States"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16617-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16617-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16617-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T01:59:30Z","timestamp":1786067970000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-16617-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16617"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16617-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"16 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The trial was submitted to and approved by the Ethics Committee of the Albert-Ludwigs-Universit\u00e4t Freiburg on 14.06.2022. The transition to CTIS took place on 27.09.2024. The study is conducted in accordance with the ethical principles of the Declaration of Helsinki and complies with the ICH guidelines on Good Clinical Practice (GCP) as well as applicable regulatory requirements, including the Clinical Trial Regulation (CTR No. 536\/2014), local privacy laws, and the General Data Protection Regulation (GDPR).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"OG, CaS, BH, MC, CJ, VR, HKA, UG, SL, JK, SJ, JaK, MdW, DMK, LO, US, OS, SW, CK, LK, MS, AG, and RW declare that they have no competing interests. The following authors declare competing interests: CS [Advisory Boards: Novartis, Idorsia; Consultancy: Roche], JHM [Advisory Boards: Pfizer, Daiichi Sankyo, GSK, Otsuka; Lecture fees: BMS, Pfizer, Celgene, Novartis, Astellas, Jazz Pharmaceutics, BeiGene; Congress support: Alexion, Astellas, Daiichi Sankyo, Pfizer, Celgene, Jazz Pharmaceutics, Novartis], ID [Honoraria: MSD, Novartis, Otsuka, BMS; Consultancy: BeOne, BMS, AbbVie; Travel grants: Johnson and Johnson, BeOne, Novartis], FT [Honoraria: AbbVie, Astellas, BMS, Jazz Pharmaceuticals; Advisory Boards: AbbVie, Agile, BMS, Daiichi Sankyo, Jazz Pharmaceuticals, Novartis], PlR [Honoraria: AbbVie, Janssen-Cilag, Novartis; Congress support: AbbVie, Janssen-Cilag; Advisory Boards: Janssen-Cilag, Novartis], LLT [Honoraria: AOP, BMS, GSK, Novartis; Advisory Boards: Astellas, Blueprint, BMS, GSK, Jazz Pharmaceuticals, Novartis, Pfizer, Sobi; Conference fees: AbbVie, AOP, BeiGene, Gilead, Jazz Pharmaceuticals], TS [Honoraria: Pfizer, AbbVie, Jazz Pharmaceuticals, GSK, Otsuka, Novartis, Daiichi-Sankyo, Astellas; Consultancy: AbbVie, Takeda, Astellas, Amgen, Bristol-Myers Squibb, Gilead, Ridgeline Discoveries, Pfizer, Jazz Pharmaceuticals, Servier, Daiichi-Sankyo, Otsuka; Congress support: AbbVie, Jazz Pharmaceuticals, Novartis, Servier], FG [Research funding to institution: ASTRA, Boehringer Ingelheim, BMS, Lilly, Novartis, Roche, MSD, Pfizer, Takeda, Siemens, Amgen, GSK, Sanofi, Regeneron, Daiichi-Sankyo; Consultancy, Honoraria and Travel grants: ASTRA, Boehringer Ingelheim, BMS, Lilly, Novartis, Roche, MSD, Pfizer, Takeda, Siemens, Amgen, GSK, Sanofi, Regeneron, Daiichi-Sankyo, Beigene; Travel grants: IPSEN; Advisory boards: ASTRA, Boehringer Ingelheim, BMS, Lilly, Novartis, Roche, MSD, Pfizer, Takeda, Siemens, Amgen, GSK, Sanofi, Daiichi-Sankyo, Beigene], PS [Honoraria: Abbvie, Amgen, AstraZeneca, BMS, Novartis; Consultancy: Abbvie, Amgen; Speakers\u2019 Bureau: Abbvie, Amgen, Astra Zeneca, Incyte; Research funding to institution: Abbvie, Pierre Fabre; Travel grants: Abbvie, Pierre Fabre, Sobi; Stocks: Novartis; Other Relationship: Abbvie, Amgen, BMS, Incyte, Gilead Sciences, AstraZeneca, Lilly Medical, Merck Serono, MSD, Pfizer, Roche Pharma AG, Novartis, Takeda, Johnson and Johnson, Janssen, Daiichi Sankyo, Orion Health, BeiGene, Stemline Therapeutics], JT [Advisory Boards: Astellas, Janssen, Sanofi; Travel grants: AbbVie, Amgen, AstraZeneca, BeiGene, Sanofi], MH [Research funding to institution: AbbVie, Bayer Pharma AG, Jazz Pharmaceuticals, Glycostem, PinotBio, Servier, Toray; Honoraria: Astellas, Daiichi Sankyo, Otsuka, Pfizer, Servier; Consultancy: Abbvie, Ascentage Pharma, Astellas, Daiichi Sankyo, Janssen, Miltenyi, Servier], HD [Research funding to institution: AbbVie, Astellas, BMS, Jazz Pharmaceuticals, Servier, Syndax; Travel grants: Servier; Consultancy: AbbVie, CHARM Therapeutics, Otsuka, Servier, Syndax], ML [Honoraria: AbbVie, Astex, Janssen-Cilag, Otsuka, Syros, Cheplapharm, Johnson and Johnson; Research funding to institution: EORTC].","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"941"}}